Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $150,788 | $120,951 | $43,517 | $16,544 |
| % Growth | 24.7% | 177.9% | 163% | – |
| Cost of Goods Sold | $23,056 | $21,535 | $8,651 | $3,484 |
| Gross Profit | $127,732 | $99,416 | $34,866 | $13,060 |
| % Margin | 84.7% | 82.2% | 80.1% | 78.9% |
| R&D Expenses | $37,823 | $30,353 | $23,922 | $39,554 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $145,598 | $119,404 | $89,855 | $89,135 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$9,480 | -$9,211 | -$3,407 | -$31 |
| Operating Expenses | $173,941 | $140,546 | $110,370 | $128,689 |
| Operating Income | -$46,209 | -$41,130 | -$75,504 | -$115,629 |
| % Margin | -30.6% | -34% | -173.5% | -698.9% |
| Other Income/Exp. Net | -$17,300 | -$17,354 | -$21,037 | -$12,860 |
| Pre-Tax Income | -$63,509 | -$58,484 | -$96,541 | -$128,489 |
| Tax Expense | $57 | $600 | $19,718 | $301 |
| Net Income | -$63,566 | -$59,084 | -$116,259 | -$128,790 |
| % Margin | -42.2% | -48.8% | -267.2% | -778.5% |
| EPS | -1.17 | -1.22 | -2.63 | -3.93 |
| % Growth | 4.1% | 53.6% | 33.1% | – |
| EPS Diluted | -1.17 | -1.22 | -2.63 | -3.93 |
| Weighted Avg Shares Out | 54,388 | 48,416 | 44,175 | 32,792 |
| Weighted Avg Shares Out Dil | 54,388 | 48,416 | 44,175 | 32,792 |
| Supplemental Information | – | – | – | – |
| Interest Income | $752 | $66 | $1,515 | $3,574 |
| Interest Expense | $18,119 | $17,408 | $20,240 | $16,403 |
| Depreciation & Amortization | $1,309 | $445 | $1,571 | $3,543 |
| EBITDA | -$44,900 | -$40,685 | -$73,933 | -$108,543 |
| % Margin | -29.8% | -33.6% | -169.9% | -656.1% |